ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For treatment of BCR–ABL-positive acute lymphoblastic leukaemia or lymphatic blast crisis of CML, TBI-containing regimens are generally preferred due to the higher irradiation sensitivity of lymphoid blasts and due to the risk of relapse in the central nervous system (Granados et al, 2000).